Skip to main content

Month: January 2022

Water Ways Signs Largest Smart Irrigation Projects in Company’s History Totaling CAD$6,700,000 With Recurring Customer

2021 Cotton Project In Uzbekistan.2021 Cotton Project In Uzbekistan.NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“WWT” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producersis pleased to announce the signing, effective January 29, 2022, of two cotton drip irrigation projects in Uzbekistan with a total value of CAD$6,700,000.The projectsare repeat orders from a recurring customer who ordered a CAD$4,000,000 system in 2021, validating the quality of the Company’s products, service and customer relations. The value of the first project in the Surkhandarya province of Uzbekistan...

Continue reading

Greenlight Re Innovations Receives In-Principle Approval to Establish Insurtech-focused Syndicate 3456

GRAND CAYMAN, Cayman Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) — Greenlight Re Innovations (“GRI”), part of Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”), has received ‘in-principle’ approval from Lloyd’s to establish an insurtech-focused syndicate. Syndicate 3456, which will commence operations in the second quarter of 2022, will be established under the innovative “Syndicate-in-a-box” (SIAB) model. It will be managed by Asta, the leading third-party managing agent at Lloyd’s. Greenlight Re Innovations has built a market-leading reputation in early stage insurtech and has made 20 investments to date. Syndicate 3456 will enable Greenlight Re to provide capacity to its growing portfolio of insurtechs. The Company will appoint Andy Gladwin as active underwriter for Syndicate 3456. Andy, who has over...

Continue reading

Point of care Diagnostics Market Size worth USD 36.21 billion by 2028 | Size, Share, Growth, Trends & Forecast

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l’Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) — The global Point of care Diagnostics Market size is projected to reach USD 36.21 billion by 2028, exhibiting a CAGR of -1.9% during the forecast period. The prevalence of several chronic disorders and the incorporation...

Continue reading

Membranes Market Expected Worth USD 10.73 Billion by 2028 | Membranes Industry Growth, Demand, Outlook and Forecast Report by Fortune Business Insights™

Companies covered in membranes market are TORAY INDUSTRIES, INC. (Japan), DuPont (U.S.), SUEZ (France), KOCH (U.S.), Pentair plc (U.S.), TOYOBA (Japan), Hydranautics – A Nitto Group Company (U.S.), Pall Corporation (U.S.), Seccua GmbH (Germany), Synder Filtration (U.S.), and more players profiled Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) — The global membranes market is expected to reach USD 10.73 billion in 2028, exhibiting a CAGR of 6.3% during the forecast period. The growth is anticipated to be swelled by its increasing usage in the pharmaceutical and biomedical industries. They help in lowering the concentration of effluent stream and recovering significant substrate or intermediate. Fortune Business Insights™ gives this information in a published report titled, “Membranes Market, 2021-2028.” The report further mentions...

Continue reading

Ozop Energy Solutions Receives Department of Insurance Approval

EV Insurance Company, Inc. DBA OZOP Plus Preparing for Launch Florida, NY, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ozop Energy Solutions. (OZSC), (“Ozop” or the “Company”), today announced its’ subsidiary, EV Insurance Company, Inc. has been granted a Conditional Certificate of Authority (the “CCA”) to operate as an insurance company by the Delaware Department of Insurance (the “DOI”) as of January 4, 2022. The Company also announced that on January 7, 2022, OZOP Plus was approved as the DBA for EV Insurance Company, Inc. The CCA will become final upon Ozop Plus meeting certain capital and surplus criteria of the DOI and continue to meet the accounting standards as set forth in the application for the Certificate of Authority. The Company has in hand the necessary capital and surplus required by the Delaware DOI. As previously announced...

Continue reading

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for a SARS-CoV-2 vaccine. The NHP pilot study follows the generation of encouraging mouse data and will evaluate the Company’s lead vaccine formulations for safety, immunogenicity and protection against SARS-CoV-2. In completed preclinical studies, Celsion demonstrated safe and efficient immune responses...

Continue reading

Tornado Global Hydrovacs Poised to Grow in 2022

Facility Enhancement, Management & Financial Strengthening, Product Line Extension CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado”, the “Company” or “we”) (TGH: TSX-V) is pleased to announce that it has strategically positioned itself for growth in 2022 and beyond. Over the past several months, Tornado has focused on implementing five strategic initiatives: (i) restructuring our management team by recruiting some of the top managers in the industry; (ii) relocating from a leased facility to a much larger and well equipped, owned facility in a better location; (iii) expanding our product line to match the needs of the excavation industry; (iv) taking a new approach to the way we distribute our products; and (v) strengthening our financial position to help fund the growth. “These strategic...

Continue reading

Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date

BATON ROUGE, La., Jan. 31, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the fourth quarter and year ended December 31, 2021, after the market closes on February 23, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 24, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through March 24, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13726704. A live webcast of the call will be accessible through the Company website on the Investor Relations section at http://investors.amedisys.com. About...

Continue reading

ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial DataImmix Biopharma, Inc. (NASDAQ:IMMX)Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumorsAn image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.  LOS ANGELES, Jan. 31, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has initiated IMX-110 Good Manufacturing...

Continue reading

CUMULUS MEDIA Announces Conference Call to Discuss Fourth Quarter and Full Year 2021 Operating Results

ATLANTA, Jan. 31, 2022 (GLOBE NEWSWIRE) — Cumulus Media Inc. (NASDAQ: CMLS) will host a conference call on Wednesday, February 23rd at 4:30 PM ET to discuss its fourth quarter and full year 2021 operating results. A press release containing a summary of these results will be issued before the call at approximately 4:00 PM ET. To participate in the conference call, please register in advance using this link. NetRoadshow (NRS) is the service provider for this call. Registration requires a one-time only email address verification. Upon completing registration, a calendar invitation will follow with call access details, including a unique PIN, and replay details. The conference call will also be broadcast live in listen-only mode through a link on the Company’s investor relations website at www.cumulusmedia.com/investors. This link...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.